Ardelyx (ARDX) Q4 2025 earnings summary

Executive summary

• Achieved all 2025 strategic priorities, including accelerating IBSRELA growth, executing XPHOZAH strategy, expanding the pipeline, and delivering strong financial performance.

• IBSRELA revenue grew 73% year-over-year to $274.2 million in 2025, establishing it as a key growth engine.

• XPHOZAH revenue was $103.6 million in 2025, with total dispenses up 9% and paid dispenses (excluding Medicare) up 41% year-over-year.

• Launched two new development programs, including next-generation NHE3 inhibitor RDX10531 and a phase III trial for chronic idiopathic constipation (CIC).

• Maintained strong cash position and generated positive cash flow in the second half of 2025.

Financial highlights

• Total 2025 revenue was $407.3 million, up 22% from $333.6 million in 2024.

• IBSRELA revenue reached $274.2 million, up 73% year-over-year; XPHOZAH revenue was $103.6 million, down 36% due to loss of Medicare Part D reimbursement.

• Other revenues, including product supply, licensing, and non-cash royalty, totaled $29.5 million, more than doubling year-over-year.

• Net loss for 2025 was $61.6 million ($0.26 per share), compared to $39.1 million ($0.17 per share) in 2024.

• Ended 2025 with $264.7 million in cash, cash equivalents, and short-term investments, up from $250.1 million at 2024 year-end.

Outlook and guidance

• 2026 IBSRELA revenue guidance: $410–$430 million, representing at least 50% year-over-year growth.

• 2026 XPHOZAH revenue guidance: $110–$120 million.

• 2026 product revenue guidance is $520–550 million, representing 38% year-over-year growth at the low end.

• IBSRELA projected to reach $1 billion in revenue by 2029, with a 38% CAGR.

• Cash position sufficient to fund planned operating expenses and reach consistent positive cash flow.